It's the Brian Larry Show on WNYC. Good morning again, everyone.

Now we'll revisit a rapidly evolving topic that continues to get so much attention,

culturally, medically, and financially.

The technical term is GLP1 agonist medications, but they're more commonly known by the brand names

OZempic, Ragovi, or Manjaro, or by the active ingredients, semaglutide, a class of medication

created to treat diabetes.

But they carry a socially desirable side effect, easy weight loss.

These drugs are seemingly everywhere, as I don't have to tell you, yet incredibly elusive in a certain way.

Maybe you've seen them advertised in subway cars, in speculative conversations about celebrities, or you've

personally discussed the pros and cons of using these drugs with your doctor, or use them

yourselves on label or off. Perhaps you've come across headlines describing revolutionary

impacts like, can weight loss drugs such as as osempic also treat addiction and dementia

from the guardian we talked about that one or will the ozempic era change how we think about being

fat and being thin from the new yorker we had the writer of that article on there's a new york time

story just today about their potential for treating kidney disease.

But while the discussion is endless, the supply is not.

Limited supply and growing demand have made the brand name GLP1 medications difficult to come by,

even if you can afford what is frequently a $1,000 sticker price.

So with all of this hype and demand and exclusivity, it shouldn't come as a shock that companies

providing semaglutide medications have become the darlings of Wall Street.

Earlier this week, did you see this?

The telehealth company, Hymns and

...